Although the primary goal of this work is to exploit somatic mutations in BLM and CHEK2, it is possible that 2ME2, ATTM and LCS-1 may also be effective in familial cancers, in much the same manner that PARP1 inhibitors are being evaluated in the context of familial breast and ovarian cancers harboring inherited defects in BRCA1/2. This evidence concerns the gene CHEK2 and ovarian carcinoma.